


Healthcare News Roundup: Ophthalmology
HSMN NewsFeed - 14 Sep 2007
Bausch & Lomb Boston(R) XO2 Gas Permeable Lens Material Gains FDA Clearance for Daily Wear
Bausch & Lomb Boston(R) XO2 Gas Permeable Lens Material Gains FDA Clearance for Daily Wear
HSMN NewsFeed - 12 Sep 2007
Ophthalmic Imaging Systems Announces Non-Binding Agreement to Acquire MediVision
Ophthalmic Imaging Systems Announces Non-Binding Agreement to Acquire MediVision
HSMN NewsFeed - 7 Sep 2007
Bausch & Lomb Launches the Stellaris(TM) Vision Enhancement System in Europe at ESCRS 2007
Bausch & Lomb Launches the Stellaris(TM) Vision Enhancement System in Europe at ESCRS 2007
HSMN NewsFeed - 27 Aug 2007
Advanced Medical Optics Hires Richard J. DeRisio as Vice President, Global Regulatory Affairs
Advanced Medical Optics Hires Richard J. DeRisio as Vice President, Global Regulatory Affairs
HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
HSMN NewsFeed - 13 Aug 2007
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
HSMN NewsFeed - 7 Aug 2007
BioElectronics Corporation Announces Distribution Agreement With Barron Medical
BioElectronics Corporation Announces Distribution Agreement With Barron Medical
HSMN NewsFeed - 3 Aug 2007
Gebauer Medizintechnik GmbH Obtains CE Approval for its New Single Use SL Keratome
Gebauer Medizintechnik GmbH Obtains CE Approval for its New Single Use SL Keratome
HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
HSMN NewsFeed - 27 Jul 2007
Akorn, Inc. Announces FDA Approval of Ketotifen Fumarate Ophthalmic Solution, 0.025%
Akorn, Inc. Announces FDA Approval of Ketotifen Fumarate Ophthalmic Solution, 0.025%
